By Lauren Martz, Executive Director, Biopharma Intelligence

Atlas-backed Judo Bio emerged from stealth with $100 million and an siRNA delivery platform to overcome the challenges of delivering drugs to the kidney, but it's not just a renal disease company. The first priority is developing therapies for systemic diseases by knocking down genes in specific kidney cells.

Many genetic medicine companies target therapies to the liver, even therapies for systemic diseases. The organ produces a variety of disease-associated proteins released into circulation, and it's a natural target for the DNA/RNA therapies with preferential uptake by the hepatocytes. ...